The Bioreagent and Cell Culture Core Facility supports cancer related research that requires in vitro experiments, provides reagents for cell culture and prepares bioreagents that are produced by cells grown in the facility. Recently, the Cell Culture Core facility was reorganized to introduce new services of producing bioreagents that were identified as high priority by the investigators during last year's survey. The Core Facility now grows suspension cultures of hybridoma cells in large quantities and produces purified monoclonal antibodies. A recently acquired News Brunswick Bioreactor made the growing of cells in large quantities possible at substantial savings. The facility is in the process of developing and evaluating lipofectin preparations for cell transfection at highly reduced costs. Additional available services are the preparation of specialized serum products, LB matrix coated culture dishes, and Ampicillin /R plates. Studies will be conducted to evaluated the feasibility of producing recombinant proteins, cytokines and growth factors. The Core Facility continues to provide established services of cell culture media preparations in large batches and their distribution at five convenient locations, testing for mycoplasma contaminations, drug testing using cytotoxity and cell proliferation assays, bulk purchase of tissue culture additives, growing attached cells in large quantities using roller bottles, and provides assistance in all techniques related to cell cultures. The Facility is one of the most widely used shared resources, utilized by 62 faculty members, and provides substantial savings of 45% to 90%.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014089-26
Application #
6443835
Study Section
Project Start
1980-04-01
Project End
2005-11-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
$91,598
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121

Showing the most recent 10 out of 842 publications